Johnson & Johnson (NYSE: JNJ) didn't have an exceptional 2024; in fact, it was one of the worst-performing stocks on the ...

Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...

Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

Guggenheim maintained a Neutral rating on Johnson & Johnson (NYSE:JNJ) but increased the stock's price target from $162.00 to $166.00. The adjustment follows the release of the company's ...

The healthcare leader is also an excellent income stock. Johnson & Johnson has increased its dividend payout for 62 consecutive years, making it a Dividend King. Between Johnson & Johnson's strong ...

Guggenheim analyst Vamil Divan raised the firm’s price target on Johnson & Johnson to $166 from $162 and keeps a Neutral rating on the ...

Guggenheim analyst Vamil Divan maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target of ...

Johnson & Johnson ( JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to ...

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...

The institutional investor owned 3,686 shares of the company’s stock after purchasing an additional 100 shares during the quarter. Strategic Investment Advisors MI’s holdings in Johnson ...

Accel Wealth Management boosted its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 23.5% during the fourth quarter, according to the company in its most recent 13F filing with the ...

Breaking Down Johnson & Johnson's Financial Performance Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size ...